Levomilnacipran (<= 80 mg); Vilazodone(<= 20 mg)/Strong CYP3A4 Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your liver processes your antidepressant.
What might happen:
The amount of antidepressant in your blood may increase and cause more side effects than normal.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together. Your doctor may want to change the dose of your antidepressant. Let your doctor know right away if you develop agitation, hallucinations, muscle twitching/stiffness/tightness, rapid heartbeat, high or low blood pressure, sweating or fever, nausea or vomiting, diarrhea, abnormal bleeding or bruising, difficulty urinating or the inability to urinate, seizures or convulsions, signs of mania (greatly increased energy, trouble sleeping, racing thoughts, reckless behavior, unusually grand ideas, excessive happiness or irritability, talking more or faster than usual).Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Fetzima (levomilnacipran) US prescribing information. Forest Pharmaceuticals, Inc. October, 2019.
- 2.Viibryd (vilazodone hydrochloride) US prescribing information. Forest Laboratories Inc. January, 2017.
- 3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 4.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2019..
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.